Comments: Without controlling for the effects of other treatments, selecting a random drug to determine a particular effect in a relatively small subpopulation of patients has statistical challenges (type 2 errors) that are hard to ignore. The findings of this surveillance study can only suggest a potential association between metformin and AAA growth inhibition, which would require a randomized, controlled trial to answer definitively. Many other drugs toting similar effects have failed under intense investigation.
Bacterial Profile in Human Atherosclerotic Plaques
Lindskog Jonsson A, Hållenius FF, Akrami R, Johansson E, Wester P, Arnerlov C, et al. Atherosclerosis 2017; 263:177-83. Conclusions: There were no major differences in bacterial DNA amount or microbial composition between carotid plaques from asymptomatic and symptomatic patients or between different plaque regions, suggesting that other factors are more important in determining plaque vulnerability.
Summary: Several studies have confirmed the presence of bacterial DNA in atherosclerotic plaques, but its contribution to plaque stability and vulnerability is unclear. In this study, the bacterial plaque profile is investigated to determine if there was a difference between patients who were asymptomatic versus symptomatic and whether there were local differences in the microbial composition within the plaque. Plaques removed by carotid endarterectomy from asymptomatic (n ¼ 11) and symptomatic patients (n ¼ 22) were divided into three different regions known to show different histologic vulnerability: (A) upstream of the maximum stenosis, (B) site for maximum stenosis, and (C) downstream of the maximum stenosis. Bacterial DNA composition in the plaques was determined by performing 454 pyrosequencing of the 16S ribosomal RNA genes, and total bacterial load by quantitative polymerase chain reaction. The sections taken at maximum stenosis were significantly more often of a histologically vulnerable phenotype (82% of 33 sections) compared with upstream (18% of 33 sections) and downstream sections (53% of 30 sections; P < .05). The presence of bacterial DNA was confirmed in the atherosclerotic plaque by quantitative polymerase chain reaction analysis of the 16S ribosomal RNA gene. There was no observed difference (P ¼ NS) in the amount between asymptomatic and symptomatic patients or different plaque regions A, B, and C. Unweighted UniFrac distance metric analysis revealed no distinct clustering of samples by patient group or plaque region. Qualitative filtered sequences were clustered into operational taxonomic units from five different phyla with the majority of the operational taxonomic units belonging to Proteobacteria (48.3%) and Actinobacteria (40.2%). There was no difference between asymptomatic and symptomatic patients, or plaque regions, when analyzing the origin of DNA at phylum, family, or operational taxonomic unit level (P ¼ NS).
Comments: Atherosclerosis is a systemic inflammatory process that might be connected to bacterial infection of local vascular cells, or at a distant site, that then upregulates an immune response. Owing to small patient numbers in this study, there is a risk of a type 2 error hiding a true microbial role in atherosclerosis; however, based on most current data, a direct correlation with a particular bacterial pathogen or family of pathogens seems unlikely. 
Results of the

Conclusions:
The fenestrated ANACONDA stent-graft system offers acceptable technical success rates, midterm efficacy, and durability with respect to aneurysm sac regression, target vessel patency, overall mortality, and reintervention rates. The rate of graft limb occlusion is of concern, especially in case of particularly complex aortic anatomies.
Summary: The fenestrated ANACONDA endograft (Vascutek, Inchinnan, UK) was introduced with the potential advantages of complete repositioning and lack of stent material on the main aortic body to allow more versatility. Because few data are available on its performance, the objective of this study was to assess its midterm results in the treatment of complex aortic aneurysms. This retrospective multicenter observational study gleaned from prospectively collected data includes 86 consecutive patients from >16 centers (82 men; mean age, 73.4 6 8.1 years; 16 [18.6%] symptomatic aneurysms) treated with the custom-made fenestrated ANACONDA endograft from December 2010 to October 2015. The primary endpoint was mortality. Secondary endpoints were technical success in the short term and long term, and morbidity. Two hundred ninety-two visceral/renal vessels were reconstructed with a mean number of 3.4 6 0.6 target vessels per patient with successful reconstruction in 99.3% of the cases (290/292 vessels). Dividing the patients into those without (group 1) versus those with extension to the celiac trunk (group 2, complex), the latter group had excessive neck angulation (4.4% vs 14.6%; P ¼ .002), and required a longer operative time (average, 87 minutes; P ¼ .0001) but similar rates of graft repositioning (w79%). Perioperative technical success was achieved in 86.0% (74/86 patients); this rate was significantly lower in more complex aneurysms with 95.6% in group 1 [43/45 patients] versus 80.5% in group 2 (33/41 patients; P ¼ .03). In-hospital and 30-day mortality rates were 3.5% (three patients) and 7.0% (six patients), respectively. Kaplan-Meier analysis was used for pertinent long-range outcomes with log-rank comparisons. Unless contraindicated, computed tomography angiography was obtained at 1, 6, and 12 months, and then yearly. At 12 and 24 months, the estimated overall survival rate was 88.3% and 85.2%, the target vessel patency rate was 97.2% and 96.3%, and the freedom from aneurysmrelated reintervention rate was 96.3% and 88.0%, respectively. No aneurysm rupture or graft migration was noted at 24 months. At 24 months, there were seven type II endoleaks (12.7%) and a significant reduction in aneurysm maximum transverse diameter in 70.4%. Five limb occlusions occurred at the 1-year and one at the 2-year follow-up (7.0%). Limb occlusions were more common in group 2 (0% vs 12.2%; P ¼ .03 at 1 year), representing the majority of required reinterventions (97.7% vs 77.2%; P ¼ .017 at 2 years).
Comments: This real-world experience using the ANACONDA fenestrated endograft provides previously unavailable information on the midterm performance of the device. A technical success of only 80% when treating extensive disease (to the celiac trunk) is concerning, and suggests that improvements are needed for this cohort of patients. The limb occlusion rate is also of concern, and may again reflect pushing the limits of the device in unfavorable anatomic conditions. Lessons learned by these early investigations will undoubtedly allow improvements and refinements in design and patient selection. Conclusions: Drug-eluting bioresorbable vascular scaffolds (BVS) were associated with increased rates of composite device-oriented adverse events and device thrombosis cumulatively at 2 years and between 1 and 2 years of follow-up compared with metallic everolimus-eluting stents (EES) when used for coronary interventions.
Summary: Drug-eluting BVS offer the potential to improve long-term outcomes of percutaneous coronary intervention owing to complete bioresorption and at 1 year had safety and effectiveness outcomes similar to metallic drug-eluting coronary stents. A systematic review and metaanalysis of randomized trials in which patients were randomly assigned to everolimus-eluting Absorb BVS or metallic EES and followed up for at least 2 years sought to determine whether drug-eluting BVS are as safe and effective as drug-eluting metallic stents within 2 years after implantation. MEDLINE, Cochrane database, ClinicalTrials.gov, and other literature sources, abstracts and presentations from major cardiovascular meetings up to April 1, 2017, were used to identify relevant studies. The primary efficacy outcome measure was the device-oriented composite endpoint (cardiac mortality, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization), and the primary safety outcome measure was definite or probable device thrombosis. Individual patient data from the four ABSORB trials were used for landmark and subgroup analysis and multivariable modelling. Seven randomized trials were found in which 5583 patients were assigned to Absorb BVS (n ¼ 3261) or metallic EES (n ¼ 2322) and followed up for 2 years. BVS had higher 2-year relative risks of the device-oriented composite endpoint than did EES (9.4% [304/3217] vs 7.4% [169/2299]; relative risk, 1.29; 95% confidence interval [CI], 1.08-1.56; P ¼ .0059). These differences were driven by increased rates of target vessel-related myocardial infarction (5.8% vs 3.2%; relative risk, 1.68; 95% CI, 1.29-2.19; P ¼ .0003) and ischemia-driven target lesion revascularization (5.3% vs 3.9%; relative risk, 1.40; 95% CI, 1.09-1.80; P ¼ .0090) when using BVS with nonsignificant differences in cardiac mortality. The cumulative 2-year incidence of device thrombosis was higher with BVS than with EES (2.3% vs 0.7%; relative risk, 3.35; 95% CI, 1.96-5.72; P < .0001). Landmark analysis between 1 and 2 years also showed higher rates of the device-oriented composite endpoint (3.3% vs 1.9%; relative risk, 1.64; 95% CI, 1.03-2.61; P ¼ .0376) and device thrombosis (0.5% vs 0%; P < .0001) in BVS-treated patients. By multivariable analysis (among other variables), a reference vessel diameter of <2.25 mm was an independent predictor of a deviceoriented composite endpoint.
Comments: Although this study deals with coronary interventions, stent designs used in the coronary system generally make their way to the peripheral vasculature and sporadic studies in the peripheral system have been reported with minimal or modest success reported. This study suggests that drug-eluting bioabsorbable stents are not as safe or effect as metallic stents in the mid and long term. Recent information suggests that proper target vessel selection (>2.25 mm in diameter), additional procedural detail (high-pressure postdilatation), and long-term dual antiplatelet therapy may improve results. It is questionable whether this technology is currently ready for widespread use in any location, but refinements are certain to come. Conclusions: Initial to midterm results of fenestrated endovascular aortic repair (f-EVAR) and multibranched EVAR (t-Branch) were overall technically feasible with perioperative mortality and high rates of freedom from aneurysm-related death. The incidence of spinal cord ischemia (SCI) was significantly higher with t-Branch repairs not fully prevented by spinal cordeprotective measures.
Clinical Outcomes of Spinal
Summary: In this single-center retrospective study, the clinical outcomes of elective f-EVAR and t-Branch on morbidity and mortality during total endovascular aortic repair for thoracoabdominal aortic aneurysms is evaluated. Eligible patients required reconstruction of four branches. Between July 2006 and June 2015, 9 (Crawford classification types
, and V [n ¼ 18]) were repaired. Excluding those with Crawford type IV thoracoabdominal aortic aneurysms (t-Branch device not applicable), 44 patients were analyzed comparing the 30 f-EVAR and 14 t-Branch repairs. Spinal cord drainage was selective (f-EVAR 26.7%, t-Branch 35.7%) but provided for all type II thoracoabdominal aortic aneurysms, prior aortic surgery, and internal iliac artery occlusion in addition to standard medical therapy protective protocols in all patients. Follow-up was 1, 6, and 12 months, and yearly, including computed tomography angiography. The primary endpoint was 30-day mortality and the secondary endpoints were freedom from aneurysm-related death and secondary interventions (Kaplan-Meier method). Multivariate analysis determined the risk factors associated with perioperative SCI. Technical success was 96.7% with f-EVAR and 100% with t-Branch, with a 30-day mortality of 3.3% and 7.1%, respectively (P ¼ NS). The incidence of perioperative SCI was higher with t-Branch (n ¼ 5; 35.7%) than with f-EVAR (n ¼ 2; 6.7%; P ¼ .04). Endoleaks were more prevalent with f-EVAR (n ¼ 9 [30.0%], with seven interventions for type III at fenestration site) than with t-Branch (n ¼ 1 type III [7.1%]; P ¼ .046). Rates of freedom from aneurysm-related death after 1 year for f-EVAR and t-Branch were 96.7% and 92.9% and after 3 years were 88.8% and 92.9% (P ¼ .982), respectively. There was no difference in secondary intervention rates, although there was a trend toward less in the t-Branch group. The risk of SCI remarkably increased in the presence of risk factors, including procedure (t-Branch), maximum short axis of $65 mm, coverage length of $360 mm, internal iliac artery occlusion, and $5 sacrificed intercostal arteries. SCI even occurred with spinal cord drainage, so other preventive measures may need to be developed in the authors' opinion.
Comments: The f-EVAR device has challenges at the fenestration sites resulting in type III endoleaks requiring reinterventions. The use of the t-Branch device has some technical benefits in that main body positioning requires less precision and cannulation of the mesenteric and renal arteries is less challenging with a secure attachment to the main device, resulting in fewer reinterventions. However, based on its design, longer lengths of the thoracic aorta are covered and this seems to impact spinal cord ischemia negatively. Even though risk factors for SCI are identified, the authors did not find spinal cord drainage as totally protective, so other causes (emboli) or new SCI protective maneuvers need to be developed. All this being stated, TAA endograft repair (either design) is an acceptable alternative to open repair based on these results.
